Hypertension Journal

Register      Login

VOLUME 3 , ISSUE 3 ( July-September, 2017 ) > List of Articles


Biomarkers in Congestive Heart Failure: Clinical Importance

Amal K Banerjee

Citation Information : Banerjee AK. Biomarkers in Congestive Heart Failure: Clinical Importance. Hypertens J 2017; 3 (3):118-124.

DOI: 10.5005/jp-journals-10043-0082

License: CC BY 3.0

Published Online: 01-09-2016

Copyright Statement:  Copyright © 2017; The Author(s).


How to cite this article

Banerjee AK. Biomarkers in Congestive Heart Failure: Clinical Importance. Hypertens J 2017;3(3):118-124.

  1. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001 Mar;69(3):89-95.
  2. Heart failure. JACC Heart Fail 2013 Feb;1(1):1-20.
  3. Surfing the biomarker tsunami at JACC: heart failure. JACC Heart Fail 2013 Jun;1(3):213-215.
  4. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Intern Med J 2008 Feb;38(2):101-113.
  5. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008 Sep;10(9):824-839.
  6. Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure. J Card Fail 2011 Sep;17(9):729-734.
  7. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract 2006 May;56(526):327-333.
  8. Neuroendocrine testing in community patients with heart disease: plasma N-terminal proatrial natriuretic peptide predicts morbidity and mortality stronger than catecholamines and heart rate variability. Scand J Clin Lab Invest 2004;64:619-628.
  9. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010 May;55(19):2062-2076.
  10. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003 Mar;107(9):1278-1283.
  11. Use of biomarkers to “guide” care in chronic heart failure: what have we learned (so far)? J Card Fail 2011;17:622-625.
  12. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med 2010 Mar;170(6):507-514.
  13. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009 Sep;158(3):422-430.
  14. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail 2011 May;4(3):246-256.
  15. Extracellular matrix fibrotic markers in heart failure. Heart Fail Rev 2010 Jul;15(4):319-329.
  16. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 2000 Nov;102(22):2700-2706.
  17. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 2009 May;119:2471-2479.
  18. Biomarkers of inflammation in heart failure. Heart Fail Rev 2010 Jul;15(4):331-341.
  19. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003 Nov;108(19):2317-2322.
  20. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 2010 May;12(5):484-491.
  21. Increased 90-day mortality in patients with acute heart failure with elevated copeptin. Circ Heart Fail 2011 Sep;4(5):613-620.
  22. Prognostic utility of plasma neutrophil gelatinase-associated lipcalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 2011 Aug;13(8):846-851.
  23. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart 2010 Aug;96(16):1297-1302.
  24. Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J Am Coll Cardiol 2006 Nov;48(9):1733-1741.
  25. Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure. Eur Heart J 2012 Sep;33(18):2317-2324
  26. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008 Oct;7(10):827-840.
  27. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem 2012 Jan;58(1):267-273.
  28. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am Heart J 2006 Jul;152(1):94-101.
  29. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur Heart J 2011 Jul;13(7):718-725.
  30. Multimarker approach for the prediction of heart failure incidence in the community. Circulation 2010 Oct;122(17):1700-1706.
  31. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008 May;358(20):2107-2116.
  32. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail 2012 Mar;5(2):183-190.
  33. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013 Oct;62(16):e147-e239.
  34. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37(27):2129-2200.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.